Compagnie Lombard Odier SCmA Buys Shares of 1,300 Natera, Inc. (NASDAQ:NTRA)

Compagnie Lombard Odier SCmA bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,300 shares of the medical research company’s stock, valued at approximately $206,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Wellington Management Group LLP grew its holdings in Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after acquiring an additional 85,236 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Maverick Capital Ltd. boosted its position in shares of Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after acquiring an additional 269,706 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock valued at $156,092,000 after acquiring an additional 246,246 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Sanford C. Bernstein lifted their price target on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. Piper Sandler lifted their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Guggenheim boosted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Barclays assumed coverage on Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price for the company. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Insider Activity

In other news, insider John Fesko sold 663 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 9,682 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total value of $1,548,926.36. Following the transaction, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 305,454 shares of company stock valued at $51,290,625. Company insiders own 7.60% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $173.39 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a fifty-two week low of $68.03 and a fifty-two week high of $183.00. The stock has a 50 day moving average price of $167.75 and a two-hundred day moving average price of $142.83. The company has a market capitalization of $22.89 billion, a P/E ratio of -98.52 and a beta of 1.66.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the previous year, the firm earned ($0.95) earnings per share. The business’s revenue was up 63.9% compared to the same quarter last year. Analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.